Cart
sales@molnova.com
Ralaniten triacetate
CAS No. 1637573-04-6
Ralaniten triacetate( —— )
Catalog No. M34834 CAS No. 1637573-04-6
Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 449 | In Stock |
|
| 5MG | 392 | In Stock |
|
| 10MG | 655 | In Stock |
|
| 25MG | 1416 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2325 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRalaniten triacetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionRalaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
-
DescriptionRalaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7.
-
In VitroRalaniten triacetate (EPI-506) targets the N-terminal domain of the androgen receptor (AR), and is used for metastatic castration-resistant prostate cancer (mCRPC) research. EPI-506 is a first-in-class, highly-specific small molecule that binds to a novel target on the AR, the N-terminal domain (NTD) and directly inhibits AR transcriptional activity by blocking the interaction of the AR with transcriptional proteins
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1637573-04-6
-
Formula Weight521
-
Molecular FormulaC27H33ClO8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (191.94 mM; Ultrasonic )
-
SMILESCC(=O)OC[C@H](COc1ccc(cc1)C(C)(C)c1ccc(OC[C@@H](CCl)OC(C)=O)cc1)OC(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2(6):453-467. Published 2019 Sep 26.?
molnova catalog
related products
-
AR antagonist 1
AR antagonist 1 is a potent antagonist of the androgen receptor. It binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266.
-
ONC1-13B
ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells.
-
GLPG-0492
A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM.
